Ocular Therapeut Stock Price, News & Analysis

Ocular Therapeutix (NASDAQ:OCUL) reported Q2 2025 financial results and business updates, highlighting significant progress in its retinal disease programs. The company reported a cash balance of $391.1 million as of June 30, 2025, bolstered by a $97 million raise through its ATM facility, extending runway into 2028.

Key financial metrics include total net revenue of $13.5 million (18.1% decrease YoY) and a net loss of $67.8 million ($0.39 per share). The company's flagship AXPAXLI™ trials for wet AMD are progressing well, with SOL-1 topline data expected in Q1 2026 and SOL-R data in 1H 2027. AXPAXLI aims to be the first product with a superiority label in wet AMD, potentially allowing dosing every 6-12 months.

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on retina treatments, has scheduled its Q2 2025 earnings conference call for Tuesday, August 5, 2025, at 8:00 AM ET. The company will discuss its business progress and financial results for the quarter ended June 30, 2025.

The call will be accessible via U.S. dial-in (1-877-407-9039), international dial-in (1-201-689-8470), and webcast. A replay will be available on the company's Investor Relations page for at least 30 days following the presentation.

Ocular Therapeutix (NASDAQ: OCUL) announced its participation in three major scientific conferences in July and August 2025. The company will present at the 8th Annual OIS Retina Innovation Summit, ASRS 2025 43rd Annual Scientific Meeting in Long Beach, CA, and Women in Ophthalmology (WIO 2025) in Amelia Island, Florida.

Key presentations will focus on the company's OTX-TKI (axitinib hydrogel) treatment for diabetic retinopathy, including data on retinal leakage assessment and macular fluid outcomes. Notable speakers include Chief Strategy Officer Sanjay Nayak, Chief Development Officer Peter K. Kaiser, and other medical experts.

Ocular Therapeutix (NASDAQ: OCUL) has unveiled new corporate branding to reflect its transformation into a retina-focused company. The rebranding features a new logo with a circular "O" representing the eye and retina, along with a full-spectrum color palette symbolizing human vision.

The company's primary focus is on disrupting retinal disease treatment, particularly wet age-related macular degeneration (AMD), which affects 1.8 million people in the U.S. Their investigational therapy, AXPAXLI™ (OTX-TKI), aims to address the limitations of current treatments that require up to 12 injections yearly and often lead to complications like fibrosis and atrophy.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation at Clinical Trials at the Summit 2025, scheduled for June 21, 2025, in Las Vegas. The company will deliver multiple presentations focused on their OTX-TKI program, including Phase 1 study results of sustained-release axitinib hydrogel for wet AMD, updates on SOL-1 and SOL-R pivotal Phase 3 trials, and safety and efficacy data from the HELIOS Phase 1 study for diabetic retinopathy. Key company representatives, including CSO Sanjay Nayak and CDO Peter K. Kaiser, will participate in various sessions and panel discussions covering topics from clinical trial results to regulatory guidance and industry innovation. The presentations will showcase Ocular's developments in ophthalmology treatments and their potential impact on patient care.

Ocular Therapeutix (NASDAQ: OCUL) announced the imminent closure of enrollment for SOL-R, its second registrational trial evaluating AXPAXLI™ for wet age-related macular degeneration (wet AMD). The trial, targeting at least 555 subjects across approximately 100 sites in the U.S., Argentina, India, and Australia, will evaluate AXPAXLI dosed every 6 months versus aflibercept every 8 weeks. This follows the completion of SOL-1, the company's first registrational trial, in December 2024, which remains on track for top-line readout in Q1 2026. Both FDA-aligned trials are designed to support an NDA submission for AXPAXLI, with potential for a superiority claim and 6- to 12-month dosing schedule. The primary endpoint of SOL-R aims to demonstrate non-inferiority in mean change in best corrected visual acuity from baseline between AXPAXLI and aflibercept at Week 56.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in four major investor conferences in May 2025. The company's Executive Chairman, President and CEO, Dr. Pravin U. Dugel, will present at:

• RBC Capital Markets Global Healthcare Conference (May 20, 2:35 PM ET)
• HC Wainwright BioConnect Investor Conference (May 20, 4:30 PM ET)
• Mizuho Neuro & Ophthalmology Summit (May 21, one-on-one meetings)
• Stifel Virtual Ophthalmology Forum (May 27, 3:00 PM ET)

Live webcasts for the RBC Capital Markets, HC Wainwright, and Stifel fireside chats will be available on the company's website under the Events and Presentations section.

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 2025 financial results and provided updates on its AXPAXLI™ development programs. The company's SOL trials for wet AMD are progressing well, with SOL-1 showing exceptional retention and on track for 1Q 2026 topline data. SOL-R enrollment remains strong following optimization to ~555 subjects. The company received positive FDA feedback for AXPAXLI in NPDR and is planning next steps for NPDR and DME indications. Financially, Ocular reported $349.7M in cash as of March 31, 2025, providing runway into 2028. Q1 2025 results showed total revenue of $10.7M, down 27.6% YoY, primarily due to decreased DEXTENZA sales. The company posted a net loss of $64.1M ($0.38 per share), compared to $64.8M loss in Q1 2024. R&D expenses increased to $42.9M from $20.7M due to clinical trial costs.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in major investor and scientific conferences in May 2025. The company's leadership team, including Executive Chairman Dr. Pravin Dugel, will present at the Citizens JMP Life Sciences Conference (May 7) and Bank of America Global Healthcare Conference (May 13).

The company will have significant presence at key scientific events including Eyecelerator, ARVO 2025, and Retina World Congress. Notable presentations will focus on their axitinib hydrogel (OTX-TKI) research for diabetic retinopathy and macular degeneration. Multiple studies will be presented, including results from the HELIOS trial and research on retinal leakage assessment.

Key executives participating include Chief Medical Officer Dr. Waheed, Chief Business Officer Saroj, and Chief Strategy Officer Dr. Nayak. The presentations will showcase Ocular's advances in novel drug delivery approaches for retinal conditions.